Gynecologic Cancers

A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

One of the first HPV self-collection solutions has been approved by the FDA, which can identify women at risk of developing cervical cancer.

The FDA has approved tisotumab vedotin-tftv for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

A pilot study proved that a nurse-coordinated approach shows promise in treating more than just 1 symptom among patients with cancer.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.

The FDA has granted priority review to mirvetuximab soravtansine for folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.

Christina M. Wilson, PhD, CRNP, WHNP-BC, shares how providers can help their patients feel empowered during their treatment.

Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

Melanie Taylor, APRN, and Mark Lin, APRN, share how they optimize strategies in caring for patients with lymphedema.

The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.

The median progression-free survival was not reached with atezolizumab plus chemotherapy vs 6.9 months in the placebo group of patients with advanced or recurrent endometrial cancer.

The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.

Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.

Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.

Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.

Many Americans with health insurance are not fully covered for frontline procedures to treat lymphedema—a debilitating condition that often affects patients with cancer.

Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.

Hyperthermic intraperitoneal chemotherapy, also known as hot chemotherapy bath, showed a long-term overall survival improvement in patients with stage III primary epithelial ovarian cancer.

Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.

Kjersten Dosumu, DNP, MS, AGPCNP-BC, explains why investigators are optimistic about treating uterine leiomyosarcoma with olaparib and temozolomide.

The median progression-free survival among patients in the intention-to-treat population who received niraparib was 24.8 months compared with 8.3 months among patients who received placebo.

Relacorilant in combination with nab-paclitaxel did not meet the statistical significance threshold for progression-free survival vs nab-paclitaxel alone.

Olaparib plus temozolomide was associated with a 27% overall response rate among 22 patients with pretreated uterine leiomyosarcoma.